
EXHIBIT F





UNITED STATES PARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNEY DOCKET NO.

 09/093, 972
 06/09/99
 NYCE
 3
 P6641031

HM2270608

VIVIANA AMIEL, PH.D. EPIGENESIS PHARMACEUTICALS, INC. 7 CLARKE DRIVE CRAMBURY NJ 05812 EXAMINER

EPPS, J

ART UNIT PAPER NUMBER

1638

AILED:

DATE MAILED:

By sue 1/4/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

11. Other:

Application NO.

Continuation of 3. NOTE: Applicants have made additional changes to the claims that were not previously agreed upon during the last telephonic interview held 5-21-01.

1) Claim 164 was amended to recite "increased levels of, adenosine or adenosine receptors," instead of "increased levels of adenosine." Additionally, claim 164 was also amended to recite oligos anti-sense to "a gene encoding or regulating the expression of a protein" instead of "a gene encoding a protein," these two changes alone to claim 164 raise new issues that would require further consideration due to new matter since neither change is supported by the specification as filed.

2) Claim 173 was amended to recite wherein at least one oligonucleotide is effective to alleviate hyper-responsiveness to, and/or increased levels of adenosine or adenosine receptors, and was further amended to recite oligos anti-sense sense to a gene controlling expression of a protein associated with hyper-responsiveness to and/or increase levels of adenosine or adenosine receptors. Applicant's specification does not indicate that they are not in possession of such oligos. Therefore, the invention as a whole would have been prima facle obvious at the time of fiting over these changes would raise new issues under 35 USC § 112, first paragraph for new matter.

3) Claims 185-187, and 221-222 were also amended to recite "increased levels of, adenosine or adenosine receptors," instead of "increased levels of adenosine." Again the scope of this amendment is not supported by the specification as filed and would therefore raise the issue of new matter under 35 USC § 112, first paragraph.

4) Claim 200 is amended to recite wherien the oligo comprises a fragment that has a T/U nucleic acid content of up to and including 15%. This amendment is not supported by the specification, since the specification and original claims supports only a description of the A, C and G content of the oligo, not the T/U content. This change would also raise the issue of new matter.

JOHN L. LEGUYADER
SUPERVISORY-PATENT-EXAMINER
TECHNOLOGY CENTER 1600